Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/164980Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Darbà, Josep | - |
| dc.contributor.author | Ascanio, Meritxell | - |
| dc.date.accessioned | 2020-06-09T21:30:49Z | - |
| dc.date.available | 2020-06-09T21:30:49Z | - |
| dc.date.issued | 2019-03 | - |
| dc.identifier.issn | 2211-8837 | - |
| dc.identifier.uri | http://hdl.handle.net/2445/164980 | - |
| dc.description.abstract | In the European Union companies only need to demonstrate that the risk-benefit balance of the new drug is favourable to obtain the authorization to sell new drugs. Hence a comparison with available treatments, a cost-effectiveness analysis and the place in the therapy of the new drug are not required. Therefore, it is necessary to carry out these analyses in an additional study. In Spain there is no national government agency, which conducts a centralized evaluation and makes decisions on funding and are the Pharmacy and Therapeutics committees that take mandatory decisions for the entire region. | - |
| dc.format.extent | 10 p. | - |
| dc.format.mimetype | application/pdf | - |
| dc.language.iso | eng | - |
| dc.publisher | Elsevier | - |
| dc.relation.isformatof | Versió postprint del document publicat a: https://doi.org/10.1016/j.hlpt.2019.02.004 | - |
| dc.relation.ispartof | Health Policy and Technology, 2019, vol. 8, num. 1, p. 14-23 | - |
| dc.relation.uri | https://doi.org/10.1016/j.hlpt.2019.02.004 | - |
| dc.rights | cc-by-nc-nd (c) Fellowship of Postgraduate Medicine, 2019 | - |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es | - |
| dc.source | Articles publicats en revistes (Economia) | - |
| dc.subject.classification | Terapèutica | - |
| dc.subject.classification | Anàlisi enzimàtica | - |
| dc.subject.classification | Lisosomes | - |
| dc.subject.classification | Farmacologia | - |
| dc.subject.other | Therapeutics | - |
| dc.subject.other | Enzymatic analysis | - |
| dc.subject.other | Lysosomes | - |
| dc.subject.other | Pharmacology | - |
| dc.title | Enzymatic replacement therapy for lysosomal storage disorders: Drug evaluations review in Spain | - |
| dc.type | info:eu-repo/semantics/article | - |
| dc.type | info:eu-repo/semantics/acceptedVersion | - |
| dc.identifier.idgrec | 691112 | - |
| dc.date.updated | 2020-06-09T21:30:50Z | - |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
| Appears in Collections: | Articles publicats en revistes (Economia) | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 691112.pdf | 166.81 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License
